This application is subject to PEP 1308.  Tiled 11/5/04.  Taminer.  U.S.C. § 119(a)-(d) or (f).	
the cover sheet with the communication This application is subject to PEP 1308.  Siled 11/5/04.  Caminer.  U.S.C. § 119(a)-(d) or (f).	Art Unit  1644  correspondence address pplication. If not included n will be mailed in due course. THIS
the cover sheet with the communication This application is subject to PEP 1308.  Tiled 11/5/04.  Taminer.  U.S.C. § 119(a)-(d) or (f).	correspondence address oplication. If not included n will be mailed in due course. THIS
EMAINS) CLOSED in this aper appropriate communication. This application is subject to PEP 1308.  Table 11/5/04.  Taminer.  U.S.C. § 119(a)-(d) or (f).	oplication. If not included n will be mailed in due course. THIS
aminer. U.S.C. § 119(a)-(d) or (f).	
U.S.C. § 119(a)-(d) or (f).	
U.S.C. § 119(a)-(d) or (f).	
received in Application No	 national stage application from the
	complying with the requirements
ote the attached EXAMINEF on(s) why the oath or declar	R'S AMENDMENT or NOTICE OF ation is deficient.
atent Drawing Review (PTO adment / Comment or in the c should be written on the drawi ler according to 37 CFR 1.121	Office action of ings in the front (not the back) of (d).
BIOLOGICAL MATERIAL HE DEPOSIT OF BIOLOGIC	
6. ☐ Interview Summary Paper No./Mail Da 7. ☑ Examiner's Amend	nte
	communication to file a reply f this application.  ote the attached EXAMINEF on(s) why the oath or declar bmitted.  atent Drawing Review ( PTO adment / Comment or in the distribution of the drawiter according to 37 CFR 1.121  BIOLOGICAL MATERIAL HE DEPOSIT OF BIOLOGIC  5. Notice of Informal I for the distribution of the dist

. A.

Application/Control Number: 09/159,172

Art Unit: 1644

Page 2

1) A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 11/5/04 has been entered.

The amendment and disclaimer file 11/5/04 have overcome all grounds of rejection previously stated.

2) An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Anne Collins on 2/7/05

The application has been amended as follows:

In claim 32, line 3 and claim 48, line 2 changed "a human" to --one or more human subjects--.

In claims 32 and 48, line 12 of each, inserted a comma after each recitation of "cells". In claim 35, line 14, after "antigen", inserted –of each distinct vaccine composition--. In claim 35, line 16 changed "isolated" to –selected--.

In claims 40 and 51, line 3 of each, changed "formulation" to -formation-.

3) The following is an examiner's statement of reasons for allowance: The changes to claims 32, 35 and 48, while not necessary for the understanding of the claims, have been made to

Art Unit: 1644

provide for better consistency within each claim. The changes to claims 40 and 51 have corrected an obvious typographical error; compare to original claim 8.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

- 4) Regarding the drawings, the draftsman has not reviewed these. They are considered acceptable by the examiner. Drawings are no longer subject to review by a draftsman.
- 5) Claim renumbering at issue is shown in the copy of the index of claims below examiner's signature.
- Any inquiry concerning this communication from the examiner should be directed to David A Saunders, PhD whose telephone number is 571-272-0849. The examiner can normally be reached on Mon.-Thu., 8:00 am-5:30 pm and alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571-272-0841. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

DAS

Daire a Saunder

DAVID SAUNDERS
PRIMARY EXAMINER
ART UNIT 182 /64

Claims renumbered in the same order as presented by applicant										☐ CPA			四f.D.			□ R.1.47			
Final	Original		Final	Original	4.4	Final	Original		Final	Original		Final	Original		Final	Original		Final	Original
	1			31			61	j		91			121			151			181
	2		1	32			62	1		92			122			152			182
	3			23			63			93			123			153			183
	4		2	34			64			94			124			154			184
	5		Y	35			65			95			125			155			185
	6		G	36			66			96			126	•		156			186
	1		9	37			67			97			127			157			187
	8		9	38			68	·		98			128			158			188
	9	·	11	39			69			99			129			159			189
	10		12	40			70			100			130			160			190
	11		13	41			71			101			131			161			191
	12		14	42			72			102			132			162			192
	13		15	43			73			103			133		,	163			193
	14		-3	44			74			104			134			164			194
L	15		4	45			75			105			135			165			195
	16		_5	46			76			106			136			166			196
	17		6	47			77			107			137			167	-		197
	18		16	48			78			108			138			168			198
	19		17	49			79			109			139			169			199
L	20		18	50			80			110			140			170			200
<u> </u>	21		19	51		l	81			111			141			171			201
L	<b>1</b> 2		20	52			82			112			142			172			202
L	<b>2</b> 3		21	53			83			113			143			173			203
	24			54			84			114			144			174			204
	25			55			85			115			145			175			205
	26			56			86	]		116			146			176			206
	27			57			87			117			147			177			207
	28			58			88			118			148			178			208
	29			59			89			119			149			179			209
•	30			60			90	1		120		<u> </u>	150			180			210